Mikiya Ishihara

8PUBLICATIONS
30CO-AUTHORS
Molecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 20, 2024
Evaluation of MAGE-A4 expression in breast cancer and its impact on prognosis.

Kaho Nakamura, Kanako Saito, Chihiro Higashi

|Oct 04, 2023
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.

Akira Kawai, Mikiya Ishihara, Tomoki Nakamura

|Jul 24, 2023
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).

Manabu Futamura, Takahiro Nakayama, Tetsuhiro Yoshinami

|Feb 02, 2023
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.

Mikiya Ishihara, Yoshihiro Nishida, Shigehisa Kitano

|Nov 14, 2022
Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.

Satoshi Okumura, Mikiya Ishihara, Naomi Kiyota

|Jun 29, 2022
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.

Mikiya Ishihara, Shigehisa Kitano, Shinichi Kageyama

Pageof 2

Frequent Collaborators

2 joint publications

Shigehisa Kitano

2 joint publications

Shinichi Kageyama

1 joint publications

Yasutaka Tono

1 joint publications

Takeshi Sasaki